AC Immune (ACIU) Gains from Investment Securities (2019)
AC Immune's (ACIU) quarterly Gains from Investment Securities came in at -$36900.4 in Q2 2019, up 99.18% on a QoQ basis from -$4.5 million in Q1 2019.
AC Immune (ACIU) Gains from Investment Securities (2019) Analysis & Trends
AC Immune (ACIU) has 1 years of Gains from Investment Securities data on file, last reported at -$36900.4 in Q2 2019.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to -$36900.4 in Q2 2019; TTM through Sep 2025 was -$36900.4, a N/A change from a year earlier, with the FY2025 full-year figure at -$18091.9, changed N/A from the prior year.
- Gains from Investment Securities for Q2 2019 stood at -$36900.4, up from -$4.5 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for ACIU reached as high as -$36900.4 in Q2 2019 and fell as low as -$4.5 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | AC Immune | 222.66 Mn | 222.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -36,900.39 |
| Jun 30, 2019 | -36,900.39 |
| Mar 31, 2019 | -4.52 Mn |
| Mar 31, 2019 | -4.52 Mn |